Lantheus Stock Price, News & Analysis (NASDAQ:LNTH)

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) issued its quarterly earnings results on Thursday, July, 25th. The medical equipment provider reported $0.27 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.27. The medical equipment provider earned $85.70 million during the quarter, compared to analyst estimates of $88.72 million. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. Lantheus's quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the business posted $0.25 EPS. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Lantheus.

Lantheus issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of $1.09-1.12 for the period, compared to the Thomson Reuters consensus estimate of $1.12. The company issued revenue guidance of $346-350 million, compared to the consensus revenue estimate of $360.07 million.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

News coverage about LNTH stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lantheus earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Lantheus.

Lantheus saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,410,000 shares, an increase of 6.8% from the August 30th total of 1,320,000 shares. Based on an average daily trading volume, of 432,500 shares, the days-to-cover ratio is currently 3.3 days. Approximately 3.7% of the company's shares are sold short. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Quidel (QDEL), Myriad Genetics (MYGN), Heska (HSKA), Quotient (QTNT), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), ImmuCell (ICCC), Celldex Therapeutics (CLDX), GeneNews (GNWSF), Trinity Biotech (TRIB) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Gerdau (GGB), Energy Transfer LP Unit (ET), Ares Capital (ARCC), Cypress Semiconductor (CY), Endocyte (ECYT), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD) and Anavex Life Sciences (AVXL).

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.56%), Bowling Portfolio Management LLC (0.11%), State of Alaska Department of Revenue (0.08%), Envestnet Asset Management Inc. (0.06%) and Campbell & CO Investment Adviser LLC (0.04%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Campbell & CO Investment Adviser LLC and Bowling Portfolio Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

LNTH stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Envestnet Asset Management Inc.. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $18.86.

Lantheus has a market capitalization of $732.15 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]